NCT01323946View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

April 18, 2011

Primary Completion Date

June 22, 2012

Study Completion Date

November 2, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

GSK Biologicals' investigational vaccine GSK1562902A

Three intramuscular injections

Trial Locations (6)

2145

GSK Investigational Site, Westmead

2606

GSK Investigational Site, Garran

3053

GSK Investigational Site, Carlton

5006

GSK Investigational Site, North Adelaide

119074

GSK Investigational Site, Singapore

228510

GSK Investigational Site, Singapore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY